Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 50 of 126 for:    HSV-2

Immunogenetic Modulators of Mucosal Protection From HIV-1 (Kinga)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03701802
Recruitment Status : Recruiting
First Posted : October 10, 2018
Last Update Posted : October 10, 2018
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Kenya Medical Research Institute
Information provided by (Responsible Party):
Jairam Lingappa, University of Washington

Brief Summary:
This is a single site, prospective, observational study that seeks to assess changes in mucosal immunity that occur as a result of HIV-1 exposure, HSV-2 infection, and/or pre-exposure prophylaxis (PrEP) usage to prevent HIV-1 acquisition. The study will collect mucosal and peripheral blood samples for a detailed analysis of longitudinal immune responses, while also obtaining samples for genetic characterization to understand how variants in CD101 and UBE2V1 may modulate host mucosal responses and HIV-1 infection risk.

Condition or disease
HIV Infections HSV-2 Infection

Detailed Description:

A challenge to development of HIV-1 vaccines is to better understand the natural immune mechanisms for protection from HIV-1 infection. To this end, immunologists have increasingly appreciated the importance of regulatory T cells in peripheral blood that modulate the magnitude and characteristics of the host inflammatory response including against infectious diseases. The investigators have recently identified specific host genetic variants in the genes CD101 and UBE2V1 that appear to strongly predispose to HIV-1 infection risk and may act through regulatory T cells and other immunologic pathways. Most studies of individuals who are repeatedly HIV-1 exposed but remain seronegative (HESN) have focused on immunological correlates in peripheral blood rather than mucosal immune responses. However, with genital mucosal tissues being the portal of entry for heterosexually transmitted HIV-1 infection, it is critical to understand the role of immunological responses to HIV-1 that occur in the genital mucosa. A valuable model to carry out such studies is offered by evaluation of HIV-Exposed SeroNegative (HESN) individuals, particularly in the context of heterosexual sex with a stable HIV-1 infected partner e.g., HIV-1 serodiscordant couples (SDC). In order to understand how genital exposure to HIV-1 may modulate these immune pathways, HIV-1 serodiscordant couples should be compared to heterosexual partners in concordant HIV-1 negative couples (CNC) where neither partner has HIV-1. This study seeks to address this important knowledge gap by enrolling high-risk HESN with defined heterosexual HIV-1 exposures in the context of serodiscordant partnerships compared to unexposed concordant seronegative controls. The study will prospectively collect mucosal and peripheral blood samples for a detailed analysis of longitudinal immune responses, while also obtaining samples for genetic characterization to understand how variants in CD101 and UBE2V1 may modulate host mucosal responses and HIV-1 infection risk.

Primary Objectives:

  • To identify mucosal immunoregulatory mechanisms mediating host response to heterosexual exposure to HIV-1.
  • To determine how high priority variants in CD101 and UBE2V1 modify host mucosal responses in HIV-1 exposure and infection.

Secondary Objectives:

  • Identify factors (including HIV-1 exposure, host genetic and microbiota) that modify immunoregulatory mechanisms mediating host response to HIV-1
  • Evaluate how these immunogenetic regulatory mechanisms influence other infectious and immunological outcomes
  • Evaluate the effect of PrEP on early HIV-1 disease

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Immunogenetic Modulators of Mucosal Protection From HIV-1: The Kinga Study
Actual Study Start Date : September 27, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort
HIV-1 serodiscordant couples
Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
Concordant HIV-1 negative couples
Heterosexual couples in which both partners are HIV-1 uninfected



Primary Outcome Measures :
  1. Prevalence of genital-tract tissue resident memory (TRM) cells [ Time Frame: At 6 months of follow-up ]
    We will compare frequency of CD69+ among CD8+ TRM in genital tissues between HIV-1 exposed and HIV-1 unexposed individuals


Secondary Outcome Measures :
  1. Prevalence of genital-tract tissue resident memory (TRM) cells in individuals with versus without CD101 immunoglobulin-like (Ig-like) variants. [ Time Frame: At 6 months of follow-up ]
    We will compare frequency of CD69+ among CD8+ TRM in genital tissues in individuals with versus without CD101 immunoglobulin-like (Ig-like) variants.


Other Outcome Measures:
  1. Prevalence of genital-tract tissue resident memory (TRM) cells [ Time Frame: At enrollment ]
    We will compare frequency of CD69+ among CD8+ TRM in genital tissues between HIV-1 exposed and HIV-1 unexposed individuals

  2. Prevalence of genital-tract tissue resident memory (TRM) cells in individuals with versus without CD101 immunoglobulin-like (Ig-like) variants. [ Time Frame: At enrollment ]
    We will compare frequency of CD69+ among CD8+ TRM in genital tissues in individuals with versus without CD101 immunoglobulin-like (Ig-like) variants.


Biospecimen Retention:   Samples With DNA
Genital samples Blood samples Urine samples Saliva samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
African heterosexual HIV-serodiscordant (SDC) and HIV-1 concordant negative couples (CNC)
Criteria

Inclusion criteria:

HIV-1 Uninfected Participants;

  • Age ≥18 and ≤65 and able to provide independent informed consent for research per local regulations and guidelines
  • Able and willing to provide written informed consent to be screened for and to take part in the study
  • Part of a heterosexual couple in which either one or both partners meet the study eligibility criteria for partner (HIV-1 uninfected) participants. Couples are defined by the following criteria:
  • Partners are sexually active (defined as having had vaginal intercourse with the enrolled partner at least 6 times in the last three months)
  • Partners plan to remain in the relationship for the duration of the study period.
  • HIV-1 uninfected status is based on parallel negative HIV-1 rapid tests, both at study screening and at the enrollment visit
  • Able and willing to provide adequate locator information for study retention purposes, as defined by local standard operating procedures

HIV-1 Infected Participants;

  • Of legal age to provide independent informed consent for research per local regulations and guidelines.
  • Able and willing to provide written informed consent to be screened for and to take part in the study.
  • Part of a heterosexual couple in which one partner meets the study eligibility criteria for index (HIV-1 infected) participants and the other partner meets the study eligibility criteria for partner (HIV-1 uninfected) participants
  • Current or previous use of antiretroviral therapy with unsuppressed HIV-1 viral load
  • HIV-1 infected based on positive EIA and, when available, detectable viral load.
  • No history of any clinical AIDS-defining diagnoses.
  • Able and willing to provide adequate locator information for study retention purposes, as defined by local standard operating procedures.

Exclusion criteria:

HIV-1 Uninfected Participants;

  • Abnormal serum creatinine (based on sub-Saharan African normal values)
  • Active and serious infections, including active tuberculosis infection or osteomyelitis and all infections requiring parenteral antibiotic therapy; active clinically significant medical problems including cardiac disease, pulmonary disease, diabetes requiring hypoglycemic medication; and previously diagnosed malignancy expected to require further treatment.
  • Receiving ongoing therapy with any of the following at the time of enrollment: antiretroviral therapy (ART), including nucleoside analogs, nonnucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents, interferon (alpha, beta, or gamma) or interleukin (e.g., IL-2) therapy, metformin, aminoglycoside antibiotics, amphotericin B, cidofovir, systemic chemotherapeutic agents, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (e.g., probenecid), and/or other investigational agent
  • At enrollment, has any other condition that, based on the opinion of the investigator or designee, would preclude provision of informed consent; make participation in the study unsafe; complicate interpretation of study outcome data)
  • Pregnant at the time of screening

HIV-1 Infected Participants;

  • Current or previous use of antiretroviral therapy with suppressed HIV-1 viral load
  • Currently enrolled in another HIV-1 treatment trial
  • At enrollment, has any other condition that, based on the opinion of the investigator or designee, would preclude provision of informed consent; make participation in the study unsafe; complicate interpretation of study outcome data; or otherwise interfere with achieving the study objectives.
  • Pregnant at the time of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03701802


Contacts
Layout table for location contacts
Contact: Jairam Lingappa, MD, PhD 206-520-3822 lingappa@uw.edu
Contact: Jennifer Lund, PhD 206-667-2217 jlund@fredhutch.org

Locations
Layout table for location information
Kenya
Partners in Health, Research and Development Recruiting
Thika, Kenya
Contact: Nelly Mugo, MBchB, MPH    +2542736744    rwamba@csrtkenya.org   
Principal Investigator: Nelly Mugo, MBchB, MPH         
Sub-Investigator: Bhavna Chohan, PhD         
Sponsors and Collaborators
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID)
Kenya Medical Research Institute
Investigators
Layout table for investigator information
Study Chair: Jairam Lingappa, MD, PhD University of Washington

Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Jairam Lingappa, Professor, University of Washington
ClinicalTrials.gov Identifier: NCT03701802     History of Changes
Other Study ID Numbers: STUDY00001559
R01AI129715 ( U.S. NIH Grant/Contract )
R01AI131914 ( U.S. NIH Grant/Contract )
First Posted: October 10, 2018    Key Record Dates
Last Update Posted: October 10, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: De-identified individual participant data for all outcome measures

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jairam Lingappa, University of Washington:
HIV prevention
Tenofovir Disoproxil Fumarate (TDF)/Emtricitabine (FTC)
PrEP
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases